

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claim 1 (currently amended): A method for treating a patient suffering from colorectal cancer proliferative disease, ~~said method~~ comprising administering an effective amount of epothilone B ~~the step of daily administration~~ over 1 to 14 days, ~~of a therapeutically effective amount of an epothilone~~, together with a pharmaceutically acceptable carrier, ~~to a warm-blooded animal in need of such treatment~~, wherein ~~the~~ daily administration is by continuous intravenous (i.v.) administration lasting 6 to 24 hours.

Claim 2 (canceled)

Claim 3 (currently amended): The method according to claim 1 ~~where an~~ wherein epothilone B is used in more than one treatment cycle, wherein a treatment cycle consists of a dosing period from 1 day to 2 weeks and a resting period from 6 days to 10 weeks, wherein the dosing period may not be shorter than the administration over 1 to 14 days.

Claim 4 (currently amended): The method according to claim 1 where epothilone B is used in a dose ~~in humans~~ that is between 4.0 mg/m² and 10 mg/m².

Claim 5 (currently amended): The method according to claim 1 where epothilone B is used in a dose ~~in humans~~ that is between 5 mg/m² and 10 mg/m².

Claim 6 (previously presented): The method according to claim 1 where epothilone B is used in a dose that is between 5.4 mg/m² and 8 mg/m².

Claim 7 (previously presented): The method according to claim 1 where epothilone B is used in a dose that is between between 7 mg/m² and 8 mg/m².

Claim 8 (previously presented): The method ~~for~~ according to claim 1 where epothilone B is administered by intravenous infusion over 1 to 10 days.

Claim 9 (currently amended): The method according to claim 1 where the epothilone B is administered by intravenous infusion over 1 to 7 days.

Claim 10 (currently amended): The method according to claim 1 where the epothilone B is administered by intravenous infusion over 1 to 5 days.

Claim 11 (currently amended): The method according to claim 1 where the epothilone B is administered by intravenous infusion over 1 day.

Claim 12 (currently amended): The method according to claim 1 where the epothilone B is administered by intravenous infusion over 5 days.

Claims 13-24 (canceled)

Claim 25 (currently amended): The method according to claim ~~13~~ 1 wherein the ~~tumor to be treated is a colorectal tumor that~~ cancer is refractory to standard chemotherapy.

Claims 26-27 (canceled)

Claim 28 (currently amended): The method according to claim ~~27~~ 1 where the ~~proliferative disease to be treated is a colorectal~~ cancer tumor that is refractory to ~~at least~~ 5-fluorouracil[,] and/or to standard chemotherapy.

C a l m s 2 (- 9 4 1) c a n c e l e d